|
|
Article: Antares Pharma Announces Its Licensee, BioSante Pharmaceuticals, Has Completed Phase II/III Trial for Estradiol Topical Gel Utilizing Antares Pharma's Gel Technology System.
- Article from:
- PR Newswire
- Article date:
- May 16, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Antares Pharma Inc. announced today that its licensee for its estradiol topical gel product in the United States, BioSante Pharmaceuticals, Inc. (BULLETIN BOARD: BISP) , has successfully completed its Phase II/III clinical trial of Bio-E-Gel(TM) (estradiol topical gel) for the treatment of moderate-to-severe hot flushes in menopausal women. Bio-E-Gel utilizes Antares Pharma's proprietary ATD(TM) gel technology designed to allow delivery of hormones and other products across the skin.
BioSante's Phase II/III trial was conducted in the United States and Canada as a randomized, double-blind study, comparing Bio-E-Gel to a placebo in 161 symptomatic women. This ...
Related newspaper, magazine, and journal articles:
|
|
Article: BioSante Pharmaceuticals Releases Update of LibiGel ...
Health & Beauty Close-Up;
June 18, 2009 ;
700+ words
...Antares Pharma, Inc. partner BioSante Pharmaceuticals announced that based upon ... LibiGel, which uses the Antares Pharma ATD system, an FDA approved ... an additional four years. Antares Pharma is a product development ...
|
|